
Is this your show? Claim this page
PodCred
The people behind this show
People get invited back because someone remembered they were great.
PodCred is the verified record of who made this show. A credit here means people who were there confirmed the work.
Hosts
Who is on this show?
Think of the guest you still think about. The producer who makes the host sound smart. The editor who saves every episode. If a name is missing here, that person is invisible everywhere.
Add a creditEpisodes
74 episodesESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.
In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO...
AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould.
Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Strategic Consulting & Analytics Business Unit at...
The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II
Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Brockbank to discuss what lies ahead for cancer...
Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy
Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30...
The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.
Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly...
The Power of the Early Narrative: Sue Wood on Strategic Biotech Positioning
Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts...
The Execution Problem: Alex Gray and Jacqueline Poot on Pharma Decision Intelligence.
Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the...
The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution
Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how...
Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping
In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment - particularly...
Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds
In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations. After the rapid rise and...
Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi
In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities...
AI & Competitive Intelligence in Pharma: Smarter Decision-Making with SAI MedPartners
In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy - and how organizations can move beyond data...
Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner
In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases. Michelle shares how...
Revitalizing Pharma Collaborations: The Reblozyl Case Study
In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and...
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas in modern medicine: using one-time gene editing...
Posts
No posts yet. Posts IDEA Collider: Innovation & Asymmetric Learning in Pharma shares on PodSubs, and what it publishes on Substack, YouTube and its own site, will show here.

Subscribe
Be on the front line of the show
Everything IDEA Collider: Innovation & Asymmetric Learning in Pharma sends its own people, first. Resources, announcements, behind the scenes, events, and giveaways, straight from the host. No account needed.
- The resources the host shares with subscribers
- Announcements before anyone else hears
- Behind the scenes from the team
- Events, invitations, and giveaways
- Only what the host sends, nothing else
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
















